Riccardo Panella

CSO and Scientific Founder at Resalis Therapeutics

Speaker

Riccardo Panella is an expert in RNA-based drug development, specializing in antisense oligonucleotide (ASO) therapeutics and non-coding RNA targeting. As Co-Founder and Chief Scientific Officer of Resalis Therapeutics, he drives the development of RES-010, a first-in-class ASO targeting miR-22 for obesity and metabolic disorders. His work focuses on advancing oligonucleotide-based therapies from preclinical validation to clinical translation, securing strategic pharma partnerships and guiding the company’s scientific vision.In parallel, Panella is Associate Professor at Aalborg University’s Center for RNA Medicine, where he leads a research group investigating non-coding RNA in metabolic homeostasis and RNA-targeted therapeutic strategies. Prior, he was Assistant Research Professor at the Desert Research Institute (Reno, NV), studying RNA-based interventions in cancer metabolism, and spent six years at Harvard Medical School’s Cancer Center, where he contributed to RNA-targeting drug discovery.Panella has authored multiple patents and peer-reviewed publications in the field of oligonucleotide therapeutics and is a frequent invited speaker at international conferences focused on RNA therapeutics, metabolism, and ASO-based drug development.